Search
Phosphoaminophosphonic acid guanylate ester
go.drugbank.com/drugs/DB02082ExperimentalA non-hydrolyzable analog of GTP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It binds tightly to G-protein in the presence of Mg2+.
Zebularine
go.drugbank.com/drugs/DB03068ExperimentalIt acts as a transition state analog inhibitor of cytidine deaminase by binding to the active site as covalent hydrates. … Also shown to inhibit DNA methylation and tumor growth both in vitro and in vivo.
Razuprotafib
go.drugbank.com/drugs/DB16353InvestigationalRazuprotafib, also known as AKB-9778, is a small-molecule inhibitor restoring Tie2 activation by inhibiting VE-PTP. … [L27171,L27176] In investigations against diabetes and COVID-19, razuprotafib is self-administered by patients through subcutaneous injection.
Emricasan
go.drugbank.com/drugs/DB05408InvestigationalEmricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA. … It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis.
Cilazapril
go.drugbank.com/drugs/DB01340ApprovedInvestigationalIt belongs to the angiotensin-converting enzyme inhibitors (ACE inhibitors) class of drugs. It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat.
Products: Co CilazaprilSargramostim
go.drugbank.com/drugs/DB00020ApprovedInvestigationalSubstitution of Leu23 leads to a difference from native protein.
MLN0415
go.drugbank.com/drugs/DB05183ExperimentalMLN0415 is a novel, small molecule IKK2 inhibitor, discovered by Millennium scientists. … In preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins.
(5Z,7E,9)-decatrien-2-one
go.drugbank.com/drugs/DB15619InvestigationalAn compound produced by _Fomitopsis betulina_, an edible fungus commonly called the birch polypore. Similar to [(5E,7E,9)-decatrien-2-one], it has a strong pineapple aroma.[A191116]
Adinazolam
go.drugbank.com/drugs/DB00546ExperimentalAdinazolam was first developed to enhance the antidepressant effects of [alprazolam]. It has never been approved by the FDA for clinical use.
Oxycodegol
go.drugbank.com/drugs/DB14146InvestigationalLoxicodegol was developed by Nektar Therapeutics as an opioid analgesic with low abuse potential for the treatment of chronic pain [L3263]. … The lack of abuse potential is believed to be due to the drug's slow rate of entry into brain, a unique characteristic compared to others in the opioid class [A33997, A34016].